{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:40:47Z","timestamp":1776069647153,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204293"],"award-info":[{"award-number":["82204293"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241054"],"award-info":[{"award-number":["82241054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Innovation Project of Yangtze River Delta Science and Technology Community","award":["2023CSJZN0800"],"award-info":[{"award-number":["2023CSJZN0800"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2024300445"],"award-info":[{"award-number":["2024300445"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40268-025-00534-5","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:26:59Z","timestamp":1775194019000},"page":"101-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIF-1\u03b1 siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance"],"prefix":"10.1007","volume":"26","author":[{"given":"Haojie","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunhui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3656-7143","authenticated-orcid":false,"given":"Yiqiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"2","key":"534_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020367","volume":"18","author":"G Liu","year":"2017","unstructured":"Liu G, Pei F, Yang F, et al.\u00a0Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. 2017;18(2):367.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"534_CR2","doi-asserted-by":"publisher","first-page":"e1700","DOI":"10.1016\/S2214-109X(23)00406-0","volume":"11","author":"C Frick","year":"2023","unstructured":"Frick C, Rumgay H, Vignat J, et al.\u00a0Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study. Lancet Glob Health. 2023;11(11):e1700\u201312.","journal-title":"Lancet Glob Health"},{"key":"534_CR3","doi-asserted-by":"publisher","DOI":"10.2196\/43651","volume":"9","author":"G Luo","year":"2023","unstructured":"Luo G, Zhang Y, Etxeberria J, et al.\u00a0Projections of lung cancer incidence by 2035 in 40 countries worldwide: population-based study. JMIR Public Health Surveill. 2023;9:e43651.","journal-title":"JMIR Public Health Surveill"},{"issue":"9","key":"534_CR4","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892\u2013911.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"534_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","volume":"5","author":"X Ou","year":"2024","unstructured":"Ou X, Gao G, Habaz IA,\u00a0et al. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm (2020). 2024;5(9):e694.","journal-title":"MedComm (2020)"},{"issue":"1","key":"534_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, et al.\u00a0Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"1","key":"534_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y,\u00a0et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"key":"534_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-014-0087-z","volume":"7","author":"X Yuan","year":"2014","unstructured":"Yuan X, Wu H, Han N, et al.\u00a0Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014;7:87.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"534_CR9","first-page":"404","volume":"76","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang Y, Li X, et al.\u00a0Status of hypoxia-inducible factor-1alpha expression in non-small cell lung cancer. Pharmazie. 2021;76(9):404\u201311.","journal-title":"Pharmazie"},{"key":"534_CR10","first-page":"242","volume":"13","author":"Q Qi","year":"2020","unstructured":"Qi Q, Wang C, Yang J, et al. Correlation between HIF-1\u03b1, PD-L1 and lymphatic metastasis in non-small cell lung cancer. Chin J Lung Dis (Electronic Edition). 2020;13:242\u20136.","journal-title":"Chin J Lung Dis (Electronic Edition)."},{"issue":"3","key":"534_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11596-016-1586-7","volume":"36","author":"SL Yang","year":"2016","unstructured":"Yang SL, Ren QG, Wen L,\u00a0et al. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis. J Huazhong Univ Sci Technol Med Sci. 2016;36(3):321\u20137.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"issue":"1","key":"534_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41598-020-79801-1","volume":"11","author":"Q Jin","year":"2021","unstructured":"Jin Q, Huang F, Xu X,\u00a0et al. High expression of hypoxia inducible factor 1alpha related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC. Sci Rep. 2021;11(1):1199.","journal-title":"Sci Rep"},{"issue":"5","key":"534_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378\u201389.","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"534_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3390\/cells11101694","volume":"11","author":"C Osude","year":"2022","unstructured":"Osude C, Lin L, Patel M, et al.\u00a0Mediating EGFR-TKI resistance by VEGF\/VEGFR autocrine pathway in non-small cell lung cancer. Cells. 2022;11(10):1694.","journal-title":"Cells"},{"issue":"6204","key":"534_CR15","doi-asserted-by":"publisher","first-page":"1250684","DOI":"10.1126\/science.1250684","volume":"345","author":"SC Cheng","year":"2014","unstructured":"Cheng SC, Quintin J, Cramer RA, et al.\u00a0mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684.","journal-title":"Science"},{"key":"534_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fonc.2020.00159","volume":"10","author":"K Zahra","year":"2020","unstructured":"Zahra K, Dey T, Ashish,\u00a0et al. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159.","journal-title":"Front Oncol"},{"issue":"2","key":"534_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbrc.2018.06.035","volume":"504","author":"M Wang","year":"2018","unstructured":"Wang M, Wang W, Wang J,\u00a0et al. MiR-182 promotes glucose metabolism by upregulating hypoxia-inducible factor 1alpha in NSCLC cells. Biochem Biophys Res Commun. 2018;504(2):400\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"534_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2(12):758\u201370.","journal-title":"Trends Cancer"},{"issue":"2","key":"534_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","volume":"27","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab. 2018;27(2):281\u201398.","journal-title":"Cell Metab"},{"issue":"48","key":"534_CR20","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, et al.\u00a0The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985\u201393.","journal-title":"Oncotarget"},{"issue":"6","key":"534_CR21","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong H, Chiles K, Feldser D, et al.\u00a0Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60(6):1541\u20135.","journal-title":"Cancer Res"},{"issue":"5","key":"534_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.molcel.2012.09.028","volume":"48","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Cao Y, et al.\u00a0EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell. 2012;48(5):771\u201384.","journal-title":"Mol Cell"},{"issue":"4","key":"534_CR23","first-page":"815","volume":"24","author":"X Tan","year":"2004","unstructured":"Tan X, Egami H, Ishikawa S, et al.\u00a0Relationship between the expression of extracellular signal-regulated kinase 1\/2 and the dissociation of pancreatic cancer cells: involvement of ERK1\/2 in the dissociation status of cancer cells. Int J Oncol. 2004;24(4):815\u201320.","journal-title":"Int J Oncol"},{"issue":"4","key":"534_CR24","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8714","volume":"51","author":"YX Shi","year":"2024","unstructured":"Shi Y, Lin X, Wang J,\u00a0et al. Advances of HIF-1\u03b1\/glycolysis axis in non-small cell lung cancer (review).\u00a0Oncol Rep. 2024;51(4):55.","journal-title":"Oncol Rep"},{"issue":"3","key":"534_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399\u2013408.","journal-title":"Cell"},{"issue":"3","key":"534_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cell.2007.04.019","volume":"129","author":"B Keith","year":"2007","unstructured":"Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129(3):465\u201372.","journal-title":"Cell"},{"key":"534_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122890","volume":"352","author":"N Taneja","year":"2024","unstructured":"Taneja N, Chauhan A, Kulshreshtha R,\u00a0et al. HIF-1 mediated metabolic reprogramming in cancer: mechanisms and therapeutic implications.\u00a0Life Sci. 2024;352:122890.","journal-title":"Life Sci"},{"issue":"2","key":"534_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020238","volume":"20","author":"A Nagao","year":"2019","unstructured":"Nagao A, Kobayashi M, Koyasu S,\u00a0et al. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance.\u00a0Int J Mol Sci. 2019;20(2):238.","journal-title":"Int J Mol Sci"},{"issue":"26","key":"534_CR29","doi-asserted-by":"publisher","first-page":"23111","DOI":"10.1074\/jbc.M202487200","volume":"277","author":"HS Lu","year":"2002","unstructured":"Lu HS, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111\u20135.","journal-title":"J Biol Chem"},{"issue":"36","key":"534_CR30","doi-asserted-by":"publisher","first-page":"25903","DOI":"10.1074\/jbc.M603414200","volume":"281","author":"XH Peng","year":"2006","unstructured":"Peng XH, Karna P, Cao Z,\u00a0et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1\u03b1 signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281(36):25903\u201314.","journal-title":"J Biol Chem"},{"issue":"1","key":"534_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02724-y","volume":"42","author":"TW Kao","year":"2023","unstructured":"Kao TW, Bai GH, Wang TL, et al.\u00a0Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance.\u00a0J Exp Clin Cancer Res. 2023;42(1):171.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00534-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00534-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:41:16Z","timestamp":1776066076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00534-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00534-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Haojie Jiang, Shunhui Cai, Xiaojun Zhang, Shijie Chen, Chunyan Yue, Wu Yin, and Yiqiao Hu have no known competing financial interests or personal relationships that may have influenced the work reported in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior to inclusion in the study. For cell line and database analyses, no individual patient consent was required, as data were obtained from publicly available sources (e.g., TCGA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request. Publicly available datasets (e.g., TCGA- lung adenocarcinoma, TCGA-lung squamous cell carcinoma) were also used, as referenced in the Methods section.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Custom scripts used for bioinformatics analyses are available from the corresponding author upon reasonable request. Any commercial software used (e.g., R, GraphPad Prism) is cited in the Methods section.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data curation: HJ, SC; funding acquisition: C-YY, YH; investigation: HJ; methodology: HJ; project administration: WY, CY, YH; resources: SC; supervision: WY, CY, YH; validation: HJ, SC, XZ, SC; visualization: XZ, SC; writing (original draft): HJ; writing (review and editing): HJ, SC, XZ.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}